NCT04016805Phase 2Terminated

Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax

Study sponsor: TG Therapeutics, Inc. · TGTX

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2022-05-22Actual

Enrollment · participants41Actual

Source updated2023-07-24Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Chronic Lymphocytic Leukemia

Treatments or interventions studied

UblituximabDrugAlso known as TG-1101
UmbralisibDrugAlso known as TGR-1202
IbrutinibDrugAlso known as Imbruvica
VenetoclaxDrugAlso known as Venclexta
Acalabrutinib Oral CapsuleDrugAlso known as Calquence

Primary outcomes · main study measures

measure: Rate of Undetected Minimal Residual Disease (U-MRD); description: U-MRD rate was defined as the proportion of participants who have undetectable MRD in the peripheral blood as confirmed by central lab.; timeFrame: Up to approximately 23 months

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history